AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
August 03 2022 - 7:00AM
Business Wire
Atlas' stealth-stage company will leverage AbCellera’s
technology to start and advance new drug programs with enhanced
speed and capital efficiency
AbCellera (Nasdaq: ABCL) and Atlas Venture announced a
multi-target partnership to discover therapeutic antibodies for up
to three drug targets that can be developed and commercialized by a
stealth-stage Atlas-backed company. The collaboration leverages
Atlas’ proven track record in forming innovative biotechnology
companies and AbCellera’s unique ability to quickly deliver lead
drug candidates to bring transformational new medicines to patients
faster.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220803005076/en/
"AbCellera’s clinically validated platform lets us start
discovery in a virtualized model that aligns well with our capital
efficient investment strategy,” said Steven Robinette, Ph.D.,
Venture Partner at Atlas Venture. “This partnership supports our
approach to value creation by allowing us to focus on building
companies that aim to deliver impactful medicines to patients.”
“Atlas has proven expertise in finding and transforming
innovative scientific research into exciting new biotechs,” said
Carl Hansen, Ph.D., CEO and President of AbCellera. “By eliminating
their need to build internal antibody discovery capabilities at
inception, we provide newly launched biotech ventures with a
competitive advantage that empowers them to move faster and
increase their probability of success. We look forward to working
alongside Atlas’ entrepreneurs to unlock their breakthrough science
and create new therapies for patients in need.”
Under the terms of the agreement, Atlas’ portfolio company will
have the right to develop and commercialize therapeutic antibodies
resulting from the collaboration. AbCellera will receive research
payments and will be eligible to receive clinical and commercial
milestone payments and royalties on net sales of products.
About Atlas Venture
Atlas Venture is a leading biotech venture capital firm. With
the goal of doing well by doing good, we have been building
breakthrough biotech startups for over 25 years. We work side by
side with exceptional scientists and entrepreneurs to translate
high impact science into medicines for patients. Our seed-led
venture creation strategy rigorously selects and focuses investment
on the most compelling opportunities to build scalable businesses
and realize value. For more information, please visit
www.atlasventure.com.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, please visit
www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220803005076/en/
AbCellera Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development: Murray
McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116
Atlas Kristen Margeson, Vice President of Investor Relations
and Marketing; lifesciences@atlasventure.com, +1(857)201-2700
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Apr 2023 to Apr 2024